Treatment
Cell clinical trials
We’re tracking 5,682 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06681220RecruitingPhase 1/Phase 2
Temozolomide and stenoparib for relapsed small cell lung cancer
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Palo Alto, CaliforniaAges 18 years+ - NCT06682481Recruiting
Pancreas-Liver Communication in Teens with Obesity
This study looks at how the pancreas and liver talk to each other in teens with obesity. It may help understand why some teens develop diabetes or fatty liver.
Geneva, Canton of GenevaAges 12–16 - NCT06684418Recruiting
AI to find hidden cancer spread in early lung cancer
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
ShanghaiAges 18 years+ - NCT06684600RecruitingPhase 2
Treating advanced esophageal cancer with dalpiciclib and pyrotinib
This trial tests a combination of two targeted drugs (dalpiciclib and pyrotinib) for people with advanced esophageal squamous cell carcinoma whose cancer has gotten worse during or after first chemotherapy. The goal is to see if this drug pair can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06684639RecruitingEarly Phase 1
GD2-targeted CAR T cells for neuroblastoma
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
Chengdu, SichuanAges 1–18 - NCT06685042RecruitingPhase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Rome, LazioAges 18–65 - NCT06687681RecruitingPhase 2
Natural killer cell therapy for brain tumors
This trial tests a new treatment using donated natural killer (NK) cells injected into the body to fight high-grade brain tumors. It might help people with certain types of aggressive gliomas that are newly diagnosed.
TehranAges 3–70 - NCT06687837RecruitingPhase 1
Stem cell therapy for Parkinson's disease
This trial tests whether implanting your own stem cells (made into dopamine-producing brain cells) can improve Parkinson's motor symptoms. You would need to be a candidate for brain surgery and have a stable medication routine.
Boston, MassachusettsAges 45–80 - NCT06688799RecruitingPhase 1/Phase 2
Anti-CD19 CAR T cells for refractory autoimmune diseases
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
Beijing, Beijing MunicipalityAges 3–65 - NCT06689800Recruiting
Family communication tool for kids getting transplant or cell therapy
This study looks at a family communication tool for children and teens getting stem cell transplants or cellular therapy. It helps families talk about treatment together.
St Louis, MissouriAges 8 years+ - NCT06690476RecruitingEarly Phase 1
Study of IPM514 for esophageal cancer
This trial tests a new drug called IPM514 for people with a type of esophageal cancer (squamous cell). It aims to find out if the drug is safe and effective. The trial has different groups for those who have had prior treatment and those who will have surgery after treatment.
BeijingAges 18 years+ - NCT06690697RecruitingPhase 2
Toripalimab and JS004 for advanced kidney cancer
This trial tests a combination of two drugs, toripalimab and JS004, for patients with advanced kidney cancer that has returned or spread. It aims to see if this therapy can help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT06691867Recruiting
Integrative training for sickle cell pain in teens
This study tests an integrative training program designed to help adolescents with sickle cell disease manage their pain better. It combines physical and mental techniques to reduce pain and improve quality of life.
Hartford, ConnecticutAges 12–18 - NCT06693336RecruitingPhase 2
Adjuvant chemotherapy trial for early-stage lung cancer
This trial tests a chemotherapy drug called SMS001 (a form of paclitaxel) after surgery for non-small cell lung cancer. It may help prevent the cancer from coming back.
Rochester, MinnesotaAges 18–80 - NCT06698965RecruitingPhase 2
Study of trilaciclib, envafolimab, etoposide, and carboplatin for extensive-stage small cell lung cancer
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06705023RecruitingPhase 2
Fat-derived cell therapy for heart failure
This study tests whether taking a small amount of your own belly fat (through liposuction), processing it, and injecting the cells back into your heart can improve heart function in people with chronic heart failure due to blocked arteries. The trial is for patients whose heart pumps weakly (ejection fraction of 40% or less) and who are already on standard medications.
AstanaAges 21–80 - NCT06705062RecruitingPhase 3
Reduced vs standard GVHD prevention in stem cell transplant
This trial tests whether a lower dose of a common drug (cyclophosphamide) after transplant can prevent graft-versus-host disease (a complication where donor cells attack your body) just as well as the standard dose. It also uses another medicine (anti-thymocyte globulin) after the transplant to help protect you.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06706713RecruitingPhase 2
Testing BEBT-109 for advanced EGFR exon 20 lung cancer
This trial tests an experimental pill called BEBT-109 for people with a specific type of lung cancer (EGFR exon 20 insertion mutation) that has gotten worse after chemotherapy. The study aims to see if this targeted therapy can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06707259RecruitingPhase 1
Cord blood CAR NK cells for B-cell lymphoma
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT05127824RecruitingPhase 2
Kidney cancer vaccine made from your own immune cells
This Phase 2 study tests a personalized kidney cancer vaccine made from your own immune cells. It aims to help your immune system recognize and attack clear cell kidney cancer after surgery, potentially lowering the chance of the cancer coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05424029Recruiting
Test blood and lung fluid markers to predict lung cancer return
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
Basking Ridge, New JerseyAges 18 years+ - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Los Angeles, CaliforniaAges 1–21
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,682 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.